文献速递肿瘤 PET/CT

68Ga标记整合素αvβ6靶向环肽放射性示踪剂用于胰腺癌PET显像的临床转化

Clinical Translation of a 68Ga-Labeled Integrin αvβ6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer.
PubMed 文献 · J Nucl Med · 2020-02-21

本研究开发了68Ga标记的整合素αvβ6靶向环肽(68Ga-cycratide),在BxPC-3胰腺癌小鼠模型中其肿瘤摄取显著高于线性肽(68Ga-linear-pep),部分归因于体内稳定性明显改善。5名健康志愿者(2女3男)注射后行全身PET/CT,计算了生物分布与剂量学,耐受良好;2例胰腺癌患者的初步PET/CT显示其诊断显像和术后肿瘤复发监测与18F-FDG相当。结论认为68Ga-cycratide具有良好的药代动力学和剂量学特征,有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。

要点

  • 68Ga-cycratide在BxPC-3胰腺癌小鼠模型中肿瘤摄取显著高于线性肽68Ga-linear-pep。
  • 5名健康志愿者(2女3男)注射68Ga-cycratide后全身PET/CT耐受良好,并计算了生物分布与剂量学。
  • 2例胰腺癌患者初步PET/CT显示68Ga-cycratide诊断显像与术后复发监测与18F-FDG相当。

核心结论

  • 68Ga-cycratide是一种整合素αvβ6特异性PET放射性示踪剂,具有良好药代动力学和良好剂量学特征。
  • 作者认为68Ga-cycratide有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。

研究设计与样本

  • 研究制备68Ga-cycratide,并在整合素αvβ6阳性BxPC-3人胰腺癌小鼠模型中与线性肽68Ga-linear-pep比较PET显像表现。
  • 5名健康志愿者(2女3男)注射68Ga-cycratide后行全身PET/CT,计算生物分布与剂量学。
  • 对2例胰腺癌患者行PET/CT显像,探讨68Ga-cycratide在胰腺癌诊断与治疗监测中的潜在作用。

主要发现

  • 68Ga-cycratide在BxPC-3荷瘤小鼠中的肿瘤摄取显著高于68Ga-linear-pep,至少部分归因于体内稳定性明显改善。
  • 68Ga-cycratide在原位小鼠模型中可灵敏检出胰腺癌病灶,且在全部健康志愿者中耐受良好。
  • 胰腺癌患者初步PET/CT显示68Ga-cycratide诊断显像与术后肿瘤复发监测与18F-FDG相当。

临床怎么用

  • 作者认为68Ga-cycratide有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The overexpression of integrin αvβ6 in pancreatic cancer makes it a promising target for noninvasive PET imaging. However, currently, most integrin αvβ6-targeting radiotracers are based on linear peptides, which are quickly degraded in the serum by proteinases. Herein, we aimed to develop and assess a 68Ga-labeled integrin αvβ6-targeting cyclic peptide (68Ga-cycratide) for PET imaging of pancreatic cancer. Methods:68Ga-cycratide was prepared, and its PET imaging profile was compared with that of the linear peptide (68Ga-linear-pep) in an integrin αvβ6-positive BxPC-3 human pancreatic cancer mouse model. Five healthy volunteers (2 women and 3 men) underwent whole-body PET/CT imaging after injection of 68Ga-cycratide, and biodistribution and dosimetry were calculated. PET/CT imaging of 2 patients was performed to investigate the potential role of 68Ga-cycratide in pancreatic cancer diagnosis and treatment monitoring. Results:68Ga-cycratide exhibited significantly higher tumor uptake than did 68Ga-linear-pep in BxPC-3 tumor-bearing mice, owing-at least in part-to markedly improved in vivo stability. 68Ga-cycratide could sensitively detect the pancreatic cancer lesions in an orthotopic mouse model and was well tolerated in all healthy volunteers. Preliminary PET/CT imaging in patients with pancreatic cancer demonstrated that 68Ga-cycratide was comparable to 18F-FDG for diagnostic imaging and postsurgery tumor relapse monitoring. Conclusion:68Ga-cycratide is an integrin αvβ6-specific PET radiotracer with favorable pharmacokinetics and a favorable dosimetry profile. 68Ga-cycratide is expected to provide an effective noninvasive PET strategy for pancreatic cancer lesion detection and therapy response monitoring.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Feng X, Wang Y, Lu D, et al. Clinical Translation of a 68Ga-Labeled Integrin αvβ6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer. J Nucl Med. 2020. PMID: 32086242. doi:10.2967/jnumed.119.237347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。